MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
05/21/18MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
NASDAQ GS | MYOK (Common Stock)
$48.70 + 0.50
06/18/184:02 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.